Your browser doesn't support javascript.
loading
BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity.
Ferreira, Adilson Kleber; Pasqualoto, Kerly Fernanda Mesquita; Kruyt, Frank A E; Palace-Berl, Fanny; Azevedo, Ricardo Alexandre; Turra, Kely Medeiros; Rodrigues, Cecilia Pessoa; Ferreira, Ana Carolina Franco; Salomón, Maria Alejandra Clavijo; de Sá Junior, Paulo Luiz; Farias, Camyla Fernandes; Figueiredo, Carlos Rogerio; Tavares, Leoberto Costa; Barbuto, José Alexandre Marzagão; Jorge, Salomão Dória.
Afiliação
  • Ferreira AK; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, The Netherlands. Electronic address: ferreira-kleber@usp.br.
  • Pasqualoto KF; Biochemistry and Biophysics Laboratory, Butantan Institute, São Paulo, SP, Brazil.
  • Kruyt FA; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, The Netherlands.
  • Palace-Berl F; Laboratory of Drug Design and Development, University of São Paulo, São Paulo, SP, Brazil.
  • Azevedo RA; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil.
  • Turra KM; Laboratory of Cytopathology, Department of Clinical Chemistry and Toxicology, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
  • Rodrigues CP; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil.
  • Ferreira AC; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil.
  • Salomón MA; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil.
  • de Sá Junior PL; Laboratory of Genetics, Butantan Institute, São Paulo, SP, Brazil.
  • Farias CF; Experimental Oncology Section, The Federal University of São Paulo, São Paulo, SP, Brazil.
  • Figueiredo CR; Experimental Oncology Section, The Federal University of São Paulo, São Paulo, SP, Brazil.
  • Tavares LC; Laboratory of Drug Design and Development, University of São Paulo, São Paulo, SP, Brazil.
  • Barbuto JA; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil; Cell and Molecular Therapy Center NUCEL-NETCEM, University of São Paulo, SP, Brazil.
  • Jorge SD; Laboratory of Tumor Immunology, University of São Paulo, São Paulo, SP, Brazil. Electronic address: sdjorge@usp.br.
Toxicol Appl Pharmacol ; 295: 56-67, 2016 Mar 15.
Article em En | MEDLINE | ID: mdl-26876618
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Melanoma Experimental / Sobrevivência Celular / Proteínas Proto-Oncogênicas B-raf / Hidrazinas Limite: Animals Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Melanoma Experimental / Sobrevivência Celular / Proteínas Proto-Oncogênicas B-raf / Hidrazinas Limite: Animals Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos